NCT04267822View on ClinicalTrials.gov

Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 15, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

July 31, 2023

Conditions
RSV InfectionStem Cell Transplant ComplicationsLower Resp Tract Infection
Interventions
DRUG

RV521 oral tablet

Each RV521 dose is four 50 mg dry powder blend capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)

DRUG

Placebo oral tablet

Each placebo dose is four capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04267822 - Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV | Biotech Hunter | Biotech Hunter